Clinical Trial Update: A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy [Phase 3]

View source ↗

Summary

Phase 3 study comparing A166 to Trastuzumab Emtansine (T-DM1) in HER2-positive unresectable or metastatic breast cancer; the trial is currently active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• A166
• Kadcyla (ado-trastuzumab emtansine) (ado-trastuzumab emtansine)

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING